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Abstract
Background: To clarify the clinicopathological characteristics of primary Sjögren's syndrome (pSS) with anti-
centromere antibody (ACA).
Methods: Characteristics of 14 patients of pSS with ACA were evaluated. All patients were anti-SS-A/Ro and SS-B/La 
antibodies negative (ACA+ group) without sclerodactyly. The prevalence of Raynaud's phenomenon (RP), titer of IgG 
and focus score (FS) in the minor salivary glands (MSGs) were determined. Quantification analysis of Azan Mallory 
staining was performed to detect collagenous fiber. Forty eight patients in whom ACA was absent were chosen as the 
conventional (ACA-) pSS group.
Results: Prevalence of ACA+ SS patients was 14 out of 129 (10.85%) pSS patients. RP was observed in 61.5% of the 
patients with ACA. The level of IgG in the ACA+ group was significantly lower than that of the ACA- group (p = 0.018). 
Statistical difference was also found in the FS of MSGs from the ACA+ group (1.4 ± 1.0) as compared with the ACA- 
group (2.3 ± 1.6) (p = 0.035). In contrast, the amount of fibrous tissue was much higher in the ACA+ group (65052.2 ± 
14520.6 μm2 versus 26251.3 ± 14249.8 μm2 ) (p = 1.3 × 10-12).
Conclusions: Low cellular infiltration but with an increase in fibrous tissues may explain the clinical feature of a high 
prevalence of RP and normal IgG concentration in ACA+ pSS.
Background
Primary Sjögren's syndrome (pSS) is characterized by
sicca symptoms and various extraglandular manifesta-
tions that are usually accompanied by autoantibodies,
especially anti-SS-A/Ro and SS-B/La antibodies (Abs) [1].
Except for anti-SS-A/Ro or SS-B/La antibodies, some
autoantibodies including anti-α-fodrin antibody or anti-
type 3 muscarinic acetylcholine receptor antibodies are
found in pSS [2,3]. Anti-centromere antibody (ACA) rec-
ognizes several centromere antigens of human chromo-
somes (CENP), in which CENP-B is a highly conserved
mammalian protein and is used for detection by enzyme-
linked immunosorbent assay (ELISA) [4]. Recent studies
[5,6] have demonstrated that ACA is also associated with
pSS. Although the prevalence of anti-SS-A/Ro or SS-B/La
Abs in pSS is 60-70%, ACA is reported to appear in 16-
26% of patients with pSS. Some reports [7] have shown
the clinical characteristics of ACA-positive (ACA+) pSS,
and a high frequency of Raynaud' s phenomenon (RP) has
been repeatedly reported. In addition to the low preva-
lence of RP, Katano et al [8] reported a low titer of IgG in
an ACA+ and anti-SS-A/Ro antibody-negative pSS popu-
lation.
The appearance of ACA is commonly described in
CREST syndrome (calcinosis, RP, esophageal dysmotility,
sclerodactyly, telangiectacia) or the limited type of sys-
temic sclerosis (SSc) [9]. Although the presence of ACA is
considered to be related to fibrosis of various organs, no
relationship between fibrosis and ACA in pSS is reported.
In the present study, we found the predominance of
fibrotic change of minor salivary glands (MSG) histologi-
cally in ACA+ pSS patients. Interestingly, cellular infiltra-
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tion was less prevalent in ACA+ pSS patients. These
differences are suggested to lead to the clinical character-
istics of ACA+ pSS.
Methods
Patients
Fourteen pSS patients with ACA were included in the
present study (ACA+ group). The classification of pSS
was determined by the revised criteria for the diagnosis
of pSS, as proposed by the American-European Consen-
sus group (AECG) [10]. All ACA+ pSS patients without
sclerodactyly are also seronegative toward anti-SS-A/Ro
A b  o r  a n t i - S S - B / L a  A b  i n  t h i s  s t u d y .  A l l  A C A +  p S S
patients were female, and their other clinical and serolog-
ical features are described in Table 1. The measurement
of anti-SS-A/Ro Ab, anti-SS-B/La Ab (Mesacup SS-A/Ro
test and SS-B/La Test; Medical & Biological Laboratories,
Nagoya, Japan), serum IgG concentration and ACA
(ELISA kit, Mesacup-2 test CENP-B; Medical & Biologi-
cal Laboratories, Nagoya, Japan) was performed as
described previously [5]. Serum IgG concentration was
measured by a nephelometric immunoassay. Two out of
14 ACA+ pSS patients complained fatigability and no
hematological disorders such as malignant lymphoma
was observed in the medical records. With regard to
usage of medications, 2 patients used pilocarpine hydro-
chloride, other 2 patients used cevimeline hydrochloride
hydrate and 1 patient used synthetic saliva spray as oral
medication. Regarding ophthalmic drop, 3 patients used
artificial tear drop and 1 patient used cyanocobalamin for
asthenopia.
For comparison to ACA+ pSS patients, 48 pSS patients
in the absence of ACA were selected to be the conven-
tional (ACA-) group for pathological study. The preva-
l e n c e  o f  a n t i - S S - A / R o  A b  o r  a n t i - S S - B / L a  A b  i n  t h e
conventional group was 77.1% as listed in Table 1.
Biopsy of labial salivary glands
Labial salivary gland biopsy was performed for all of the
pSS patients. Informed consent for the usage of samples
obtained by the biopsy was obtained from all the partici-
pating patients as of the commencement of the study, and
the study was conducted with the approval of the human
ethical committee of our institution. The severity of
mononuclear cell infiltration was determined using the
classifications of Chisholm & Mason [11], whereas the
focus score (FS) was also examined using a classification
determined by Greenspan [12].
Azan Mallory staining of labial salivary glands
Formalin-fixed, paraffin-embedded sections (3-μm thick)
from labial salivary glands of 14 ACA+ pSS patients and
48 ACA- pSS patients were cut and mounted onto glass
slides precoated with aminopropyltriethoxysilane (APS).
For the detection of collagenous fiber in MSG, Azan Mal-
lory staining was performed. To calculate the area of the
blue-stained lesion obtained by Azan Mallory staining,
WinROOF software (Mitani Corporation, Fukui, Japan)
was employed. Briefly, the software captured the blue sig-
nal on the samples, and the total area was automatically
calculated by WinROOF.
Statistical analysis
Serological data, FS and the calculated blue signal area in
MSGs of both groups were compared by Student's t test
or the Chi square test. A P value less than 0.05 was con-
sidered statistically significant.
Results
Clinical manifestations of ACA+ pSS patients
In our institution, the prevalence of ACA+ pSS patients
was 14 out of 129 (10.85%) pSS patients who strictly met
AECG classification criteria in our medical records,
Table 1: Background of ACA+ and ACA- SS patients in this study
ACA (+) ACA (-) P value
N (M/F) 14 (0/14) 48 (1/47) 0.59
Age 57.4 ± 9.6 58.3 ± 13.2 0.82
Follow-up period (year)¶ 6.6 ± 5.6 4.5 ± 4.6 0.16
Raynaud's phenomenon 8/13 (61.5%) 4/48 (8.3%) 1.86 × 10-5
anti-SS-A/Ro Ab or anti-SS-B/
La Ab
0/14 (0.0%) 37/48 (77.1%) 2.30 × 10-7
IgG (mg/dl) 1530.2 ± 267.1 2056.0 ± 730.2 0.018
Average of FS 1.4 ± 1.0 2.3 ± 1.6 0.035
Clinical characteristics of the ACA-seropositive and non-ACA Sjögren's syndrome (SS) patients are shown. The differences were calculated 
using Student's t test and the Chi-square test. (*; p < 0.05; statistically significant). The differences found regarded the prevalence of Raynaud's 
phenomenon, the level of IgG and the average of FS.
¶Follow-up period is duration from point of diagnosis. ACA; anti-centromere antibody, FS; focus scoreNakamura et al. BMC Musculoskeletal Disorders 2010, 11:140
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although the entire 129 pSS patients were listed with or
without examination for labial salivary biopsy.
The basic information of the ACA+ pSS patients is
indicated in Table 1. All of the registered patients were
females, and no statistically significant difference was
observed regarding gender and age between the 14 ACA+
patients (57.4 ± 9.6) and the 48 ACA- patients (58.3 ±
13.2) (p = 0.82). There was no statistical difference in fol-
low-up period from point of diagnosis between ACA+
and ACA- pSS groups. ACA- patients showed either
xerophtalmia (56.3%) or xerostomia (72.9%) with 85.7%
positivity in the Saxon test. In addition, these 3 parame-
ters showed no statistical significance between ACA- and
ACA+ pSS patients (P value determined by Chi-square
test was 0.12, 0.59 and 0.92, respectively). The prevalence
of RP in the ACA+ group was 8/13 (61.5%). Serum IgG
was 1530.2 ± 267.1 mg/dl (normal range; 870-1700),
which was within the normal limit. The serum IgG from
the ACA- group was 2056.0 ± 730.2, which showed a sta-
tistically significant difference from that of the ACA+
group (p = 0.018). Furthermore, the serum IgG from
ACA- pSS group without anti-SS-A/Ro or SS-B/La Abs
was 1615.7 ± 361.5, which was statistically similar to that
of ACA+ pSS group (p = 0.63). We also obtained quanti-
tative results regarding ACA by ELISA from 13 SS
patients; these results showed that the titer of ACA of
these patients was 157.0 ± 33.9 (normal range; <16 index).
The results of MSG biopsy showed 2 patients in grade 2,
7 patients in grade 3 and 5 patients in grade 4 according
to the Chisholm & Mason classification with the FS of 1.4
± 1.0. Compared to the FS of the 48 patients in the ACA-
group (2.3 ± 1.6), mononuclear cell infiltration was signif-
icantly lower in the ACA+ pSS patients (p = 0.035).
Increment of collagenous fiber in ACA+ pSS patients
T o  e v a l u a t e  t h e  a m o u n t  o f  c o l l a g e n o u s  f i b e r  i n  M S G ,
lesions stained blue by Azan Mallory staining were cap-
tured by an image analysis system. The MSG of the
ACA+ group showed large amounts of collagenous fiber
compared to that in the ACA- group (Figure 1). Under
certain conditions, the captured signal area of MSG from
both groups was calculated by WinROOF software. The
calculated areas in the ACA+ group and the ACA- group
were 65052.2 ± 14520.6 μm2 and 26251.3 ± 14249.8 μm2
with statistical significance, respectively (p = 1.3 × 10-12)
(Figure 2).
Discussion
Although ACA is known to appear in CREST syndrome
or limited cutaneous SSc patients with RP, its significance
in pSS remains to be clarified precisely. With regard to
the prevalence of ACA in pSS patients, Salliot C et al [13]
previously described as 4.7% in 212 pSS patients in
France. Prevalence in our data (10.85%) was statistically
higher than that of their data (p = 0.032 by chi-square
test) despite the same measurement of antibodies against
CENP-B. It might derive from genetic background or dif-
ference of ELISA kit. Our present data confirmed the pre-
vious observation that ACA+ pSS has a high prevalence
of RP despite normal IgG, which is different from ACA-
pSS, which is seropositive toward anti-SS-A/Ro Ab or
anti-SS-B/La Ab [5,8]. However, we should note that the
serum IgG from ACA- pSS group without anti-SS-A/Ro
or SS-B/La Abs and ACA+ pSS group was within normal
limit without statistical significance. These observations
suggest normal IgG might be associated with negativity
of anti-SS-A/Ro or SS-B/La Abs rather than ACA. Since
there was no statistical difference with regard to follow-
up period between ACA+ and ACA- pSS groups in this
study, we suggest that the high prevalence and normal
IgG in ACA+ pSS is specific for this disease subset. It is
speculated that fibrotic change might be dominant in
ACA+ pSS, and we have revealed for the first time using
quantitative analysis of Azan Mallory staining that collag-
enous fiber is accumulated in the MSG of ACA+ pSS
patients. In addition, a novel finding was made that there
is less mononuclear cell infiltration as determined by FS
i n  A CA +  p S S  p a t i e n t s  a s  c o m p a r e d  w i t h  c o n v e n t i o n a l
pSS patients. In rheumatoid arthritis, Oosterhout et al
Figure 1 Azan Mallory staining of anti-centromere antibody 
(ACA) + and ACA- patients with Sjögren's syndrome (SS). To detect 
the existence of collagenous fiber in minor salivary glands in SS pa-
tients, Azan Mallory staining was performed for all patients. The lower 
panels show Azan Mallory staining results of ACA+ and ACA- SS pa-
tients. To clarify the amount of collagenous fiber, the image analyzer 
WinROOF was employed. The green signal in the upper panels shows 
the captured form of blue staining produced by Azan Mallory staining. 
(Original magnification × 200).
ACA- pSS ACA+ pSS
Azan Mallory
staining
Image
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recently found the histological difference based on the
presence or absence of anti-cyclic citrullinated peptide
(CCP) antibodies in the synovial tissues that synovial tis-
sues from anti-CCP antibodies+ subjects contain more
cellular components with less fibrotic change as com-
pared with those from anti-CCP antibodies - subjects
[14]. This finding suggests that the serologic status may
reflect the histologic characteristics in autoimmune dis-
eases, and our present report is the first one involving
patients with pSS. In ACA+ pSS patients, a lower FS
appears to be associated with normal serum IgG whereas
prominent collagenous fiber accumulation correlates
with a high prevalence of RP. More recently, Bournia VK
e t  a l  [ 1 5 ]  r e p o r t e d  t h a t  h y p e r g a m m a g l o b u l i n e m i a  w a s
characteristic of not ACA+ pSS but ACA-SS subgroup,
which suggests ACA+ pSS subgroup forms intermediate
entity between ACA- pSS and SSc.
Since Miyawaki et al [9] demonstrated that 6 out of 10
pSS patients with ACA and RP developed CREST syn-
drome in the follow-up investigation, it is necessary for us
to follow-up the present 14 ACA+ pSS patients to deter-
mine whether they develop CREST syndrome in the
future. Avouac J et al [16] also previously reported that
the prevalence of secondary SS was 14% and was strongly
associated with limited cutaneous SSc. Although we
excluded limited cutaneous SSc in the present study
according to the criteria determined by LeRoy et al [17],
SSc complicated with secondary SS should be carefully
examined during follow-up period. Since data from the
above report [9] showed development of CREST syn-
drome in pSS patients with ACA, observation period of
6.6 years in this study might not be sufficient to refer to
assess accurate follow-up period for development of
CREST syndrome or limited SSc in the subset of ACA+
pSS patients. It is difficult to make mention of possibility
for development to pSS or CREST syndrome/limited SSc
unless a prospective study for ACA+ pSS subset is per-
formed. Because this is an issue in the future, it might be
difficult to cite from this study.
Conclusions
In ACA+ SS, low cellular infiltration but with an increase
in fibrous tissues may explain the clinical feature of a high
prevalence of RP and normal serum IgG concentration in
ACA+ pSS. These findings suggest that ACA+ pSS
patients were different from patients with anti-SS-A/Ro
and SS-B/La antibodies.
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Figure 2 Quantification of captured signal in minor salivary 
glands in anti-centromere antibody (ACA) + and ACA- patients 
with Sjögren's syndrome (SS). The captured green signal from 14 
ACA+ and 48 ACA- SS patients was calculated by WinROOF software 
under certain conditions. The figures represent actual measurements 
in units of μm2 under a fixed magnification ratio of the optical micro-
scope (×200). A scatter plot of the processed data is shown. Quantifi-
cation results from the patients with and without ACA showed 65052.2 
± 14520.6 μm2 and 26251.3 ± 14249.8 μm2 with significance (p = 1.3 × 
10-12). Student's t test was used for statistical evaluation. A P value less 
than 0.05 was considered statistically significant.
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